A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
for Chronic Inflammatory Demyelinating Polyneuropathy
3 locations incl. Palo Alto
Sponsor: Kite, A Gilead Company
Sex: All·Age: 18 - 75
Code: NCT07304154·Phase 1·Recruiting